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Original Article
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Glypican-3 (GPC3), the cellular membrane proteoglycan, has
been established as a tumor biomarker for early diagnosis of
hepatocellular carcinoma (HCC). GPC3 is highly expressed in
more than 70% HCC tissues detected by antibody-based
histopathological systems. Recently, aptamers, a short single-strand DNA or RNA generated from systematic evolution
of ligands by exponential enrichment (SELEX), were reported
as potential alternatives in tumor-targeted imaging and diagnosis. In this study, a total of 19 GPC3-bound aptamers were
successfully screened by capillary electrophoresis (CE)-SELEX
technology. After truncated, AP613-1 was conﬁrmed to speciﬁcally target GPC3 with a dissociation constant (KD) of
59.85 nM. When modiﬁed with a phosphorothioate linkage,
APS613-1 targeted GPC3 with a KD of 15.48 nM and could
be used as a speciﬁc probe in living Huh7 and PLC/PRF/5 imaging, GPC3-positive cell lines, but not in L02 or A549, two
GPC3-negative cell lines. More importantly, Alexa Fluor
750-conjugated APS613-1 could be used as a ﬂuorescent
probe to subcutaneous HCC imaging in xenograft nude
mice. Our results indicated that modiﬁed AP613-1, especially
APS613-1, was a potential agent in GPC3-positive tumor imaging for HCC early diagnosis.

INTRODUCTION
Hepatocellular carcinoma (HCC) is a common malignant cancer
worldwide. Several molecules have been used as tumor biomarkers
for HCC diagnosis in clinic. Besides AFP, glypican-3 (GPC3), also
called DGSX, GTR2-2, MXR7, OCI-5, SDYS, SGB, or SGBS, is the
one that is highly expressed in more than 70% of HCC patients.1
Although lowly expressed in melanoma, ovarian clear cell carcinoma,
yolk sac tumors, neuroblastoma, and hepatoblastoma, it is silenced in
breast cancer, mesothelioma, epithelial ovarian cancer, lung adenocarcinoma, cholangiocarcinoma (CCA), and normal liver tissues.2
Therefore, GPC3 might be an ideal tumor biomarker for in vivo
HCC diagnosis, especially for HCC-targeted imaging.
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The level of GPC3 in serum or tumor tissues is usually detected by
antibody-based ELISA and previously by immunohistochemical
staining. However, some obvious defects of antibody have limited
its wide use in vivo due to its high immunogenicity, easy degradation,
and high cellular cytotoxicity effect. Therefore, a novel reagent needs
to be developed as a surrogate in clinical practice. Aptamer3,4 is a kind
of agent, which can speciﬁcally target varieties of polypeptides,5 proteins,6 and living cells,7 with high afﬁnity and selectivity by virtue of
its topological secondary or tertiary structure. More importantly, aptamers exhibit numerous advantages, such as easy synthetization and
chemical modiﬁcation, high stability, non-toxicity, and non-immunogenicity.8–11 Thus, aptamers are expected to have great in vivo
application in cancer diagnosis.
By far, to our knowledge, several aptamers against HCC cells have
been reported, such as AS1411, a speciﬁc nucleolin-bound aptamer,12,13 and a series of 6-nt aptamers, which targeted GPC3 and
were isolated by cell-systematic evolution of ligands by exponential
enrichment (SELEX) containing four standard nucleobases and two
added nucleobases (2-amino-8H-imidazo[1,2-a]triazin-4-one and
6-amino-5-nitropyridin-2-one, trivially Z and P), with dissociation
constants (KD) in the range of 6–500 nM.14 The former was able to
suppress HCC by upregulating Galectin-14, and the latter could
distinguish cells that expressed GPC3 protein from those that did

Received 12 August 2017; accepted 21 September 2018;
https://doi.org/10.1016/j.omtn.2018.09.013.
9

These authors contributed equally to this work.

Correspondence: Weizhong Wu, Liver Cancer Institute, Zhongshan Hospital,
Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry
of Education, Fenglin Road 180, Shanghai 200032, China.
E-mail: wu.weizhong@zs-hospital.sh.cn
Correspondence: Jiang Lin, Liver Cancer Institute, Zhongshan Hospital, Fudan
University, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of
Education, Fenglin Road 180, Shanghai 200032, China.
E-mail: lin.jiang@zs-hospital.sh.cn

Molecular Therapy: Nucleic Acids Vol. 13 December 2018 ª 2018 The Authors.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

www.moleculartherapy.org

not. Here, we ﬁrst screened GPC3-bound single-stranded DNA
(ssDNA) aptamers based on capillary electrophoresis (CE)-SELEX,
then we truncated and modiﬁed candidates with locked nucleic acid
(LNA) substitution and phosphorothioate linkage, and we evaluated
their binding afﬁnities on GPC3-positive and GPC3-negtive cells.
AP613-1 was found speciﬁcally targeting GPC3-positive cells with a
high afﬁnity. After LNA substitution and phosphorothioate linkage,
the aptamer, especially APS613-1, showed signiﬁcantly increased afﬁnity with a KD of 15.48 nM on GPC3-positive cells. In vivo imaging
showed that tumor-speciﬁc ﬂuorescent signals were clearly observed
at nude mice upon HCC xenograft using Alexa Fluor 750-conjugated
APS613-1 at 150 min after tail veil injection. Taken together, these results suggested that APS613-1 could be used as a probe for GPC3-positive HCC imaging in vivo.

RESULTS
Characterization of Aptamer-Binding Motif against GPC3

Based on our established screening method,15 GPC3-bound aptamers
were isolated by 6 rounds of CE-SELEX in this study (Figure S1).
Finally, 19 aptamers with different nucleic acid sequences were cloned
and sequenced (Table S1).
To evaluate the afﬁnities of the screened aptamers, Huh7, a GPC3positive cell line (Figure S2), was recruited to analyze its ﬂuorescence
intensity after incubation with 1 mM FAM-labeled aptamer candidates, one by one, using ﬂow cytometry. Our results showed that 14
of 19 aptamers, such as AP602, AP603, and AP612, exhibited higher
binding abilities than that of the initial Library aptamer, suggesting
their superior afﬁnities to GPC3 protein expressed on HCC cells.
Meanwhile 5 other aptamers, AP631, AP634, AP652, AP657, and
AP691, had weakly increased binding abilities compared to the Library control (Figure 1A). After a negative selection with L02, a
GPC3-negative cell line (Figure S2), 12 aptamers except AP618 and
AP658 had over twice the ﬂuorescent signals in Huh7 cells than those
in L02 cells. Among them, AP613, AP625, AP636, AP643, and AP684
were the top 5 aptamers whose ﬂuorescence intensities in Huh7 cells
were signiﬁcantly higher than others (Figure 1B; p < 0.001), indicating
that these 5 aptamers had speciﬁc and robust GPC3-binding abilities
in living HCC cells.
To identify GPC3-binding motifs, the secondary structures of AP613,
AP625, AP636, AP643, and AP684 were predicted by DNAMAN
software ﬁrst (Figure 1C), and 7 truncated aptamers with the same
characteristic sequences as full-length ones were synthesized thereafter (Figure S3; Table S2). For example, AP613-1, a truncated form
of AP613, included a two-small-arm structure (red), while AP636-1
(red) and AP636-2 (blue), two truncated forms of AP636, both contained a long stem-loop structure (Figure 1C). Then, the afﬁnities of 5
full-length aptamers and 7 corresponding truncated ones to GPC3
were analyzed in parallel by ﬂow cytometry in Huh7 and L02 cells.
As presented in Figure 1D, the ﬂuorescence intensities of AP613-1
were remarkably enhanced, nearly 2 times those with AP613 in the
Huh7 cell line (p < 0.05). The other 6 truncated forms showed no
obvious changes in ﬂuorescence intensity when compared with their

corresponding full-length aptamers. Thus, AP613-1 was a unique
candidate with increased GPC3-binding afﬁnity for this study.
Increased Affinity and Specificity of Modified AP613-1

To protect aptamers from nuclease degradation and promote the afﬁnity in the in vivo context, two types of chemical modiﬁcations on
AP613-1 nucleotides were introduced in the study. APL613-1 was
produced when AP613-1 was modiﬁed with three LNA substitutions
in the “+” position, and APS613-1 was obtained when three phosphorothioate linkages were at both nucleotide ends in the “*” position
(Figure 2A). Then the binding abilities of FAM-labeled AP613,
AP613-1, APL613-1, and APS613-1 to Huh7 cells were evaluated
once more by ﬂow cytometry. As presented in Figure 2B, the ﬂuorescent signals of APS613-1 and APL613-1 were much stronger than
those of AP613, AP613-1, as well as the Library control, indicating
that chemically modiﬁed AP613-1 exhibited an ascending afﬁnity
on GPC3-positive cells, especially of phosphorothioate linkage.
To quantitatively determine the afﬁnities of AP613 and its derivatives,
Huh7 cells were incubated with 0, 5, 25, 100, and 500 nM FAMlabeled AP613 and its derivatives, respectively. Then the dissociation
constant KD was calculated by nonlinear regression analysis. As
shown in Figures 2C and 2D, the KD of APS613-1, APL613-1,
AP613-1, AP613, and the Library control were 15.48 ± 2.96 nM,
34.90 ± 9.59 nM, 59.85 ± 15.39 nM, 89.30 ± 19.08 nM, and 192.5 ±
70.6 nM, respectively. APS613-1, but not APL613-1, had a signiﬁcantly lower KD than those of the other three groups (p < 0.05).
That is to say, APS613-1 had the highest afﬁnity to GPC3-expressed
cells.
To identify GPC3-binding speciﬁcity of APS613-1, GPC3-positive
Huh7 and PLC/PRF/5 cell lines,2 as well as GPC3-negative L02
and A549 cells (Figure S2), were incubated with FAM-labeled
APS613-1. Our results showed that APS613-1 had similar KD on
L02 (134.8 ± 49.7 nM) and A549 cells (128.1 ± 41.3 nM), which
were almost 8- and 4-fold higher than those of Huh7 (15.48 ±
2.96 nM) and PLC/PRF/5 cells (33.15 ± 6.52 nM), respectively (Figures 2E and S4), manifesting that APS613-1 could recognize GPC3expressed cells distinctively.
HCC Cell Imaging with APS613-1

To explore the potential usage of APS613-1 in HCC imaging, direct
ﬂuorescent stainings on Huh7, PLC/PRF/5, L02, and A549 cells, as
well as HCC and adjacent noncancerous tissues, were done using
FAM-labeled APS613-1. As expected, intensive ﬂuorescent signals
were observed on the cytomembrane of Huh7 and PLC/PRF/5 cells,
yet scarcely on those of L02 and A549 cells (Figures 3A and S5).
Similar results were achieved when the cells were stained by antiGPC3 antibody (Figures 3B and S5). In addition, we performed a
transient transfection with pcDNA3.1-GPC3WT plasmid in L02 cells.
Bright green ﬂuorescent signals were also observed using anti-GPC3
antibody and FAM-labeled APS613-1 around nuclei of L02-GPC3-O
cells (Figure 3C). Meanwhile, APS613-1 and anti-GPC3 antibody exhibited similar positive staining in the membrane and cytoplasm in

Molecular Therapy: Nucleic Acids Vol. 13 December 2018

377

Molecular Therapy: Nucleic Acids

Figure 1. The Affinity and Specificity of Aptamer Candidates
(A) The binding abilities of 19 screened aptamers against GPC3-positive Huh7 cells. 14 aptamers, such as AP602, AP603, AP612, etc., had superior affinities against Huh7
cells than that of the initial Library aptamer. (B) The binding specificities of 14 high-affinity aptamers against Huh7 and GPC3-negative L02 cells. AP613, AP625, AP636,
AP643, and AP684 generated over twice stronger fluorescent signals in Huh7 cells than those in L02 cells, and their binding abilities reached significant difference (p < 0.001)
between Huh7 and L02 cells. (C) The second structures of the top 5 aptamers with the highest GPC3-binding affinities predicted by DNAMAN. The probable binding motifs
with characteristic sequences are highlighted in red or blue. (D) The differential affinities between 5 full-length aptamers and 7 corresponding truncated ones. AP613-1
generated a significant affinity with a nearly 2 times increase to Huh7 cells than that of AP613 (p < 0.05). However, similar binding affinities were found between AP613-1 and
AP613 to L02 cells. Data were mean ± SEM and representative of three independent experiments.

human HCC tissues and adjacent noncancerous tissues (Figure 4).
However, it should be mentioned that positive nuclear staining appeared in the APS613-1, but not in the anti-GPC3 antibody staining
(Figure 4). One probable reason was that APS613-1 aptamer might
exhibit more nucleus permeability than that of antibody, resulting
in a brighter green staining.
To conﬁrm the speciﬁc binding potential of APS613-1 on GPC3,
Huh7, PLC/PRF/5, L02-GPC3-O, L02, and A549 cells were ﬁrst
probed with 0.5 mM FAM-labeled APS613-1, and then they were ﬁxed
and re-probed with 5 mg/mL antibody against human GPC3. As
shown in Figure 5A, most green ﬂuorescent signals were observed
on the cytomembrane, and red ﬂuorescent signals were almost
observed in the cytoplasm in Huh7, PLC/PRF/5, and L02-GPC3-O
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cells. Next, when these cells were pre-probed with anti-GPC3 antibody and then ﬁxed and re-probed with FAM-labeled APS613-1,
red signals were observed on the cytomembrane and green signals
were in the cytoplasm in GPC3-positive cell lines (Figure 5B). Finally,
when Huh7, PLC/PRF/5, and L02-GPC3-O cells were ﬁxed with
4% paraformaldehyde and then co-incubated with FAM-labeled
APS613-1 and anti-GPC3 antibody, some orange ﬂuorescent signals
were observed (Figure 5C), indicating the co-localization of both
probes on GPC3 molecules. Therefore, our results revealed that
APS613-1 indeed bound GPC3 speciﬁcally.
High Stability and Tissue Imaging of APS613-1

To investigate the stability of aptamers, APS613-1 and the Library
control were ﬁrst incubated with human serum, and then they were

www.moleculartherapy.org

Figure 2. The Affinity and Specificity of Modified AP613-1
(A) Nucleotide sequences and chemical modification. AP613-1 was a truncated form of AP613. APL613-1 had LNA substitution in the “+” positions and APS613-1 was
modified with phosphorothioate linkage in the “*” positions. (B) Flow cytometric profiles of AP613, AP613-1, APL613-1, and APS613 as well as the initial Library aptamer
binding with Huh7 cells. APS613-1 had the highest fluorescent signals as the peak shifted remarkably from the left to the rightmost. (C and D) The binding curves and
dissociation constants (Kds) of APS613-1, APL613-1 AP613-1 (D), AP613, and the Library (D) control were 15.48 ± 2.96 nM, 34.90 ± 9.59 nM, 59.85 ± 15.39 nM, 89.30 ±
19.08 nM, and 192.5 ± 70.6 nM, respectively. APS613-1 had the lowest Kd in all five groups (p < 0.05), revealing the highest affinity to GPC3. (E) The Kds of APS613-1 on L02
and A549 cells were 134.8 ± 49.7 nM and 128.1 ± 41.3 nM, respectively, and almost 8-fold higher than that on Huh7 cells (15.48 ± 2.96 nM), manifesting its targeted binding
against GPC3. Data were mean ± SEM and representative of three independent experiments.

analyzed by their degradation rate at 0, 0.5, 1, 2, and 4 hr, respectively. Both APS613-1 and the Library control showed nearly identical bands to initial ones after 4 hr of incubation (Figure 6A).
Similar results were also observed in AP613, AP613-1, and
APL613-1 after exposure to human serum for 0, 0.5, 1, 2, and
4 hr (Figure S6). These data demonstrated that AP613 and its derivatives were highly resistant to nuclease degradation in vitro
within 4 hr and probably appropriate to be used in in vivo
applications.
To evaluate in vivo imaging of aptamers in the HCC xenograft
model, Alexa Fluor 750-conjugated APS613-1 and the Library control were injected via tail veins of nude mice. Tumor ﬂuorescent images were serially acquired at 0, 5, 30, 60, 90, 120, and 150 min after
aptamer injection in unilateral Huh7 xenograft models (Figures 6B
and 6C). Both APS613-1 and the Library control were distributed
rapidly throughout the body within 5 min (Figure 6C), and the
initial ﬂuorescence intensities (108) of APS613-1 and the Library
control at xenograft regions were 8.41 ± 0.74 and 8.77 ± 1.14,
respectively (Figure 6D). However, 150 min after injection, the signals (108) of APS613-1 at xenograft were 2.46 ± 0.26, much

brighter than those of the Library control (0.93 ± 0.31) and background (Figure 6D). The results were also conﬁrmed in sacriﬁced
xenograft tumors and vital organs at 90 min after injection (Figures
6E, S7, and S8). Signiﬁcantly stronger signals of APS613-1 in tumor
than those of the Library control were conﬁrmed, while other vital
organs showed no obvious changes. In bilateral xenograft models,
tumor ﬂuorescent images were acquired at 0 and 90 min after aptamer injection (Figures 6F–6H). Obviously, the ﬂuorescence intensity (107) of the Huh7 tumor (Figure 6G, right red circle) was
12.73 ± 1.34, signiﬁcantly stronger than that of A549 (3.83 ±
0.68; Figure 6G, right green circle) at 90 min after injection with
Alexa Fluor 750-conjugated APS613-1. However, when injected
with the Library control, the ﬂuorescent signals (  107) of Huh7
and A549 xenografts were 4.75 ± 2.03 and 5.06 ± 0.98, respectively,
showing no obvious changes (Figure 6G, left circles). Similar results
were conﬁrmed in dissected Huh7 and A549 tumors at 90 min after
aptamer injection (Figure 6I).
Taken together, APS613-1 indeed speciﬁcally recognized GPC3-positive HCC cells in our in vivo and ex vivo experiments, and it had the
potential to be used in HCC-targeted imaging in the clinic.
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Figure 3. Cell Imaging with APS613-1
(A and B) Fluorescence imaging of Huh7, L02, and A549 cells stained by FAM-labeled APS613-1, FAM-labeled Library control, and anti-GPC3 antibody. (A) Intensive
fluorescent signals were observed on the cytomembrane of Huh7 cells, yet scarcely on those of L02 and A549 cells. (B) Similar results were achieved when the cells were
stained by anti-GPC3 antibody. (C) Fluorescence imaging of L02-GPC3-O cells stained by anti-GPC3 antibody, FAM-labeled APS613-1, and Library control. Bright green
fluorescence was also observed around the nuclei of transfected cells (second row). DAPI was used for contrast staining (blue).

DISCUSSION
HCC is the fourth most common neoplasm worldwide with
increasing incidence over the last several decades, and it has the
third cancer-related mortality of all human cancers, indicating
the poor prognosis of this disease.16 Due to the asymptomatic
nature of HCC in the early stage, patients are often diagnosed
in the advanced stages and have considerably lower 5-year
survivals than those in the early stage.2 Surgical resection is one
of the few therapeutic options, but only 10%–20% of primary
HCCs are resectable at the time of diagnosis. Therefore, it
is badly needed to develop a novel and sensitive method for
HCC in vivo early diagnosis, recurrence monitoring, and prognosis
evaluation.
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GPC3, a member of the heparan-sulfate proteoglycan (HSPG) family,
is highly expressed on cytomembrane through a glycosyl phosphatidylinositol (GPI) anchor in HCC, but not in normal liver tissues.17 It
has been discovered as a sensitively serologic and pathological
biomarker for early HCC diagnosis in recent years.18 Biologically
functional studies revealed that GPC3 can stimulate HCC cell growth,
migration, and adhesion by upregulating the Wnt-signaling pathway
in an autocrine/paracrine manner.1,19–23 Therefore, GPC3 is also a
promising target for in vivo HCC imaging and cancer therapy.
At present, the levels of GPC3 in serum and tumor tissues are usually
detected by antibody diagnostic systems. Although antibodies are
sensitive and speciﬁc enough for in vitro diagnosis, they are hardly
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Figure 4. Tissue Imaging with APS613-1
Fluorescence imaging of human hepatocellular carcinomas and adjacent noncancerous tissues stained by FAM-labeled APS613-1 (A), FAM-labeled Library (A), and antiGPC3 antibody (B). APS613-1 and anti-GPC3 antibody exhibited similar positive staining in the membrane and cytoplasm in human HCC tissues and adjacent noncancerous
tissues. DAPI was used for contrast staining (blue).

used in vivo due to their high immunogenicity, poor permeability,
and instability in the body. By virtue of the secondary or tertiary
structures, nucleotide-based aptamers can target a given tumor
biomarker with high speciﬁcity and afﬁnity like an antibody. More
importantly, aptamers have great promise for repeated use in in vivo
tumor monitoring and imaging by their targeted binding potentials
without any obvious antigenicity.
It has been reported that CE-SELEX was an efﬁcient, high-resolving,
and time-saving strategy in aptamer screening.24,25 Indeed, after a
four-round selection, we successfully obtained aptamers speciﬁcally
targeting GPC3 protein. However, GPC3-bound aptamers were
dramatically enriched, and their nucleotide sequences were largely
homologized after another two-round screening. Some aptamers
had even a single base disparity in their nucleotide sequences, for
example, AP602 and A603. Therefore, puriﬁed PCR products after
a six-round CE-SELEX selection were used as the end products for
DNA sequencing.
To identify aptamer candidates ﬁtting for HCC in vivo imaging, all 19
screened aptamers were ﬁrst evaluated for their afﬁnities and speciﬁcities in vitro using several cell lines. By comparing the differences of afﬁnity from a given aptamer between GPC3-positive and GPC3-negative
cells, AP613, AP625, AP636, AP643, and AP684 were ﬁnally picked out
with enormously high afﬁnities to GPC3-postive HCC cells.

Like antibody, not every nucleotide in one aptamer is required for its
binding motif composition.26–28 Some may be necessary for the secondary structure formation or maintenance. To identify the minimal
binding motif, an aptamer would be truncated to abbreviate all unnecessary nucleotide sequences without compromising its binding
speciﬁcity and afﬁnity. Some strategies, such as partial hydrolysis
and footprinting29–31 used for the protein-binding motif analysis,
were not apt to nucleotide-binding motif analysis in aptamers.
With the development of bioinformatics, the secondary structure,
as well as the binding motif of aptamers, could be easily predicted.26,27,32,33 In theory, any truncated aptamer, with a binding
motif in the same secondary structure as the full-length ones, would
be the same or similar in its binding speciﬁcity but vary in its afﬁnity.
Therefore, the motifs of the top 5 GPC3-bound aptamers were predicted, truncated, and then re-evaluated in the study. Our preliminary
results showed that predicted motifs based on the secondary structure
were often empirical and sometimes unreliable. More parameters,
such as charges or advanced structures of aptamers, should be considered during motif analysis.
To prevent rapid nuclease degradation and promote afﬁnity in vivo,
aptamers are usually subjected to modiﬁcation. After being
substituted or encapsulated with different chemical groups, the
advanced structures and their in vivo stabilities of aptamers are significantly optimized. LNAs are similar to traditional bases, but they have
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Figure 5. Colocalization Analysis of APS613-1 to GPC3 with Anti-GPC3 Antibody
(A) Fluorescence imaging of Huh7, PLC/PRF/5, L02-GPC3-O, L02, and A549 cells stained by FAM-labeled APS613-1 first, and then fixed and re-stained by anti-GPC3
antibody. Most green fluorescent signals were observed on the cytomembrane and red fluorescent signals were almost observed in the cytoplasm in Huh7, PLC/PRF/5, and
L02-GPC3-O cells. (B) Fluorescence imaging of Huh7, PLC/PRF/5, L02-GPC3-O, L02, and A549 cells stained by anti-GPC3 antibody first, and then fixed and re-stained by
FAM-labeled APS613-1. Red signals were observed on the cytomembrane, and green signals in the cytoplasm in GPC3-positive cell lines. (C) Fluorescence imaging of Huh7,
PLC/PRF/5, and L02-GPC3-O cells co-incubated with FAM-labeled APS613-1 and anti-GPC3 antibody after being fixed with 4% paraformaldehyde. Some orange
fluorescent signals were observed.
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Figure 6. Nuclease Stability and In Vivo Imaging with APS613-1 in Nude Mice
(A) Nuclease stability of the Library and APS613-1 with human serum at 0, 0.5, 1, 2, and 4 hr. They both showed nearly identical bands to initial ones after 4 hr of incubation.
(B) Imaging of dorsal side of live mice before injection. Unilateral Huh7 tumor site is circled in red. (C) In vivo fluorescent images of Huh7 tumors in live mice after injection with
Alexa Fluor 750-conjugated Library and APS613-1 at 5, 30, 60, 90, 120, and 150 min, respectively. Both APS613-1 and the Library control were distributed rapidly
throughout the mice within 5 min, including tumor sites. At 150 min after injection, the fluorescent signals of APS613-1 at tumor sites became brighter than those of nontarget
tissues. Meanwhile, almost no signals were observed in the Library control. (D) Fluorescence intensities of ROIs after injection with Alexa Fluor 750-conjugated Library and
APS613-1 at 5, 30, 60, 90, 120, and 150 min, respectively. At 5 min, the fluorescence intensities (108) of tumor regions of the Library control and APS613-1 were 8.77 ±
1.14 and 8.41 ± 0.74, respectively. At 150 min, the fluorescence intensities (108) were reduced to 0.93 ± 0.31 and 2.46 ± 0.26, respectively (n = 3). The Library control
declined even faster than APS613-1. (E) Fluorescence imaging of Huh7 tumor tissues after mouse dissection. Much brighter signals of APS613-1 were confirmed than those
of the Library control at 90 min after injection. (F) Imaging of the dorsal side of live mice before injection in bilateral xenograft models. The Huh7 tumor site is circled in red and
the A549 tumor site is circled in green. (G) In vivo fluorescent images of bilateral tumors in live mice after injection with Alexa Fluor 750-conjugated Library and APS613-1 at
90 min. The fluorescence intensity of the Huh7 tumor (right red circle) was stronger than that of the A549 (right green circle) after injection with APS613-1, while the models
injected with the Library control showed no obvious changes (left circles). (H) Fluorescence intensities of ROIs at 90 min after injection with Alexa Fluor 750-conjugated Library
and APS613-1 in bilateral xenograft models. In the APS613-1 group, the fluorescence intensity (107) of the Huh7 tumor was 12.73 ± 1.34, significantly higher than that of the
A549 (3.83 ± 0.68, n = 3). The signals (107) of the Huh7 and A549 xenografts injected with the Library control were 4.75 ± 2.03 and 5.06 ± 0.98, respectively (n = 3).
(I) Fluorescence imaging of Huh7 and A549 tumor tissues after mouse dissection. Much brighter signals of the Huh7 tumors were confirmed than those of the A549 at 90 min
after injection with APS613-1, but there was no intensity difference in the Library group between Huh7 and A549 tumors.

a methylene bridge connecting 20 -oxygen of the ribose with 4’-carbon.
When incorporating LNA into molecular beacons, the group possesses a 25-fold enhancement in ﬂuorescence signaling.34 Kubota
et al.35 reported that both the numbers and positions of LNA substitution in the oligonucleotides were the most important factors on
DNA stability and afﬁnity. The more LNA substitutes in the central
position there were, the higher the binding efﬁciency of the nucleotide
sequence was. In antisense hybridization, oligonucleotides were often
modiﬁed with phosphorothioate to protect nucleic acid degradation
from nuclease. By modifying three to ﬁve bases with phosphorothioate at the 50 and 30 termini, the oligonucleotides would resist enzymatic degradation dramatically and then signiﬁcantly increase their
stabilities and afﬁnities. So, in this study, three bases in the central po-

sitions of AP613-1 were replaced by LNAs, or three bases at both
50 and 30 termini were replaced by phosphorothioates. After chemical
modiﬁcations, indeed, both APL613-1 and APS613-1, especially the
latter, exhibited higher binding abilities to GPC3-positive cells
compared to unmodiﬁed aptamers.
Next, APS613-1 was tested for its potential application in HCC imaging. As expected, APS613-1 exhibited similar positive staining proﬁles
of HCC cells and tissues like anti-GPC3 antibody. However, some
brighter green signals appeared in the nucleus of HCC tissues when
probed by APS613-1. To answer the puzzles, Huh7, L02, and A549
cells, after being ﬁxed by 4% paraformaldehyde, were stained with
FAM-labeled APS613-1 in parallel. Again, brighter green ﬂuorescent
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signals were observed in all nuclei of the 3 cell lines, as well as in the
membrane and cytoplasm of Huh7, but not in L02 and A549, cells
(Figure S9). A strong positive nuclear staining also was observed in
paraformaldehyde-ﬁxed Huh7 cells with AP613-1, not AP613 (Figure S10). All these results indicated that nuclear staining of aptamers
might be nonspeciﬁc and independent of GPC3 levels, cell types, and
chemically modiﬁed patterns but probably dependent on membrane
penetrability increased by paraformaldehyde ﬁxation and molecular
weights of the probes. That is to say, the truncated form of the aptamer, APS613-1, was probably more ﬁtting for living HCC imaging.
Considering the superior properties of aptamers in targeted imaging
in vivo, Alexa Fluor 750-conjugated APS613-1 was explored for in vivo
HCC imaging in nude mice. Subcutaneous Huh7 xenografts were
indeed speciﬁcally imaged at 150 min after APS613-1 injection, suggesting the aptamer could be a novel agent for GPC3-positive HCC
imaging. However, orthotopic Huh7 xenografts in nude mouse
were difﬁcult to detect because of the poor penetration of ﬂuorescent
signals in deep tissues. Therefore, APS613-1 conjugated with other
agents, such as magnetic nanoparticles (e.g., Fe3O4) or 18F, would
be more pragmatic in the clinical setting when used for in vivo
HCC imaging on an MRI or positron emission tomography/
computed tomography (PET-CT) system, with much higher sensitivity and resolution than these with ﬂuorescent imaging.36–38
In conclusion, phosphorothioate-modiﬁed AP613-1 was a novel speciﬁc probe against GPC3, and it is probably a promising agent for
in vivo GPC3-positive HCC imaging in the future.

MATERIALS AND METHODS
Aptamers and Primers

The initial ssDNA Library, PCR primers, and FAM-conjugated aptamer candidates were chemically synthesized by Sangon Biotech,
Shanghai, China. Alexa Fluor 750-conjugated aptamers were synthesized by Thermo Fisher Scientiﬁc, Shanghai, China. LNA- and phosphorothioate-modiﬁed aptamers were synthesized by Genscript
Biotech, Nanjing, China.
The ssDNA Library contained a 35-nt random sequence in the
central region, ﬂanked by the 20-nt constant region at the 50 - and
3 0 ends, respectively (5 0 -GTGACGCTCCTAACGCTGAC-N35CCTGTCCGTCCGAACCAA TC-30 ). The primers for the ampliﬁcation of double-stranded DNA were 50 -GTGACGCTCCTAACGCT
GAC-30 (forward primer, P1) and 50 -GATTGGTTCGGACGGA
CAGG-30 (reverse primer, P2). The biotinylated reverse primer
(bio-P2) at the 50 end was also prepared for the ssDNA sub-Library.

(Gibco Life Technologies, Carlsbad, CA, USA), supplemented with
10% fetal bovine serum (FBS; Gibco).
Vector and Transfection

The pcDNA3.1-GPC3WT plasmid overexpressing GPC3 protein was
a gift from Professor Z.J. Chen (Shanghai Institute of Biochemistry
and Cell Biology, Shanghai Institute for Biological Science, China).
The pcDNA3.1-GPC3WT plasmids were transfected into L02 cells using Lipofectamine 3000 Reagent according to the product manual
(Thermo Fisher Scientiﬁc, Carlsbad, CA, USA).
CE-SELEX Procedure

GPC3-bound ssDNA candidates were selected as previously
described.15 Simply, puriﬁed recombinant human glypican-3 protein
(GPC3, R&D Systems, Minneapolis, MN, USA) was mixed with the
ssDNA Library (10 mM) at the ﬁnal concentration of 50 mg/mL and
then injected into the capillary. Under the pressure of 0.5 psi and
the voltage of 8 kV, GPC3-bound aptamers were separated from
unbound ssDNAs, then collected and ampliﬁed by routine PCR.
The PCRs were set up in a ﬁnal volume of 100 mL with 2 mL template
described as above, 50 mL 2 Taq PCR MasterMix (Tiangen Biotech,
Beijing, China), 0.4 mM P1, and 0.4 mM bio-P2. The reaction was performed at 94 C for 3 min; then 15 cycles of 94 C for 30 s, 58 C for 30
s, and 72 C for 30 s; and, ﬁnally, at 72 C for 5 min for extension.
Then the ssDNA sub-Library was separated from the PCR-ampliﬁed
products using Dynabeads M-280 Streptavidin (Thermo Fisher Scientiﬁc).15 Brieﬂy, about 10 mg PCR products was incubated with
1 mg pre-washed Dynabeads for 20 min. After washing and denaturing, the Dynabead-unbound ssDNAs were precipitated, resuspended, and quantiﬁed, which served as the sub-Library ssDNAs
for the next round selection.
Cloning and DNA Sequencing

After the sixth round selection, PCR products were puriﬁed and
cloned using a previously described method.15 92 white clones were
picked out for nucleic acid sequencing by Sangon. Each was named
as AP6XX according to their serial sequencing number.
Secondary Structure Prediction and Modification

The secondary structures of aptamers were predicted by DNAMAN
software (version 5.2; Lynnon, Pointe-Claire, QC, Canada). Based
on their characteristics of secondary structures, aptamers were truncated only to retain the potential binding motif for the targeted protein. Then, the dominant truncated candidates were further modiﬁed
with LNA substitution or phosphorothioate linkage.

Cell Lines and Cell Culture

Four human cell lines were used in this study: Huh7 and PLC/PRF/5,
two liver cancer cell lines with GPC3-positive expression; L02, a
normal liver cell line with GPC3-negative expression; and A549, a
lung cancer cell line with GPC3-negative expression. All four cell lines
were purchased from the Shanghai cell bank of the Chinese Academy
of Sciences and cultured in DMEM with high glucose (DMEM-H)
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Flow Cytometry Analysis

The speciﬁc afﬁnities of GPC3-bound aptamers were assessed by ﬂuorescence-activated cell sorting (Becton Dickinson, FACScan, Mansﬁeld, MA, USA). Brieﬂy, about 1  106 cells were incubated at 37 C
for 60 min with various concentrations of 6-carboxy-ﬂuorescein
(6-FAM)-labeled aptamer candidates in 200 mL PBS buffer containing
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1% BSA. Cells were then washed twice with 0.8 mL PBS buffer to remove unbound ssDNAs and resuspended in 0.5 mL PBS buffer for
binding analysis. The ﬂuorescence intensity was analyzed by counting
10,000 events. The initial ssDNA Library was used as a negative aptamer control. L02 and A549 cell lines were used as negative cell controls. Meanwhile, cell staining with 5 mg/mL mouse anti-human GPC3
antibody (Abcam, Cambridge, MA, USA) was performed as a positive
GPC3 control. Equilibrium KD of the aptamer-cell interactions were
obtained by ﬁtting the dependence of relative ﬂuorescence intensity
of speciﬁc binding according to the following equation: Y = Bmax 
X/(KD + X). Y represented the value of relative binding, Bmax was
the maximal value of relative binding, and X was the concentration
of the aptamer. All binding assays were repeated three times.
HCC Cell and Tissue Imaging with Aptamers

Cells were seeded into 6-well confocal plates (NEST Biotech, Wuxi,
China) at an initial number of 1  105 cells/well. After a 24-hr culture,
the cells were washed with PBS buffer three times and stained with
0.5 mM FAM-labeled aptamers at 37 C in the dark for 60 min. After
thoroughly washing, the cells were imaged by a ﬂuorescence microscope (Olympus, Tokyo, Japan) or laser-scanning confocal microscope (Leica SP8, Leica Microsystems, Richmond Hill, ON, Canada).
Meanwhile, immunoﬂuorescence staining using 5 mg/mL rabbit antihuman GPC3 antibody (Abcam) was performed as a positive control.
For co-localization analysis, prior to ﬁxation, cells were incubated
with labeled aptamers or Anti-GPC3 antibody, and then they were
ﬁxed and re-incubated with antibody or aptamers.

xenograft tumor grew to 1–2 cm in diameter, all mice were randomly
divided into four groups with three mice per group. About 0.65 nmol
Alexa Fluor 750-conjugated experimental or control aptamers in
150 mL PBS buffer were injected into nude mice via a lateral tail
vein. Then, at a given time, the ﬂuorescence images of xenograft tumors in the dorsal side of nude mice were taken by the IVIS Lumina
XRMS Series III ﬂuorescence imaging system (PerkinElmer, Waltham, MA, USA). The intensities of tumor regions of interest
(ROIs) (radiance efﬁciency, [p/s/cm2/sr]/[mW/cm2]) were generated
automatically by Living Image 4.4 software and then analyzed. All animals were kept in a pathogen-free environment and fed ad lib. The
procedures for care and use of animals were approved by the Ethics
Committee of Zhongshan Hospital of Fudan University (Shanghai,
China) and all applicable institutional and governmental regulations
concerning the ethical use of animals were followed.
Statistical Analysis

Data were analyzed using GraphPad Prism 5 software. Quantitative
variables were expressed as means ± SEM and analyzed by two-way
ANOVA and Student’s t test. Results were considered statistically signiﬁcant at p < 0.05.
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